Linezolid Dosing for Corynebacterium Pneumonia
For adult patients with Corynebacterium pneumonia, use linezolid 600 mg PO or IV every 12 hours (twice daily).
Dosing Rationale
The standard linezolid dose for pneumonia is well-established at 600 mg every 12 hours, administered either orally or intravenously 1. This dosing applies to pneumonia caused by Gram-positive organisms, including Corynebacterium species. The FDA-approved pharmacokinetics demonstrate 100% oral bioavailability, allowing interchangeable use of oral and IV formulations without dose adjustment 2.
Key Pharmacokinetic Considerations
Pulmonary penetration: Linezolid achieves approximately 100% penetration into epithelial lining fluid, with concentrations in lung tissue matching or exceeding plasma levels 3. This excellent alveolar diffusion makes it particularly effective for pneumonia.
Standard adult dosing: 600 mg every 12 hours provides mean steady-state AUC₀₋₂₄ of approximately 138-154 mg·h/L in adults 2, 3
Therapeutic targets: This regimen maintains trough concentrations above 2 mg/L and peak concentrations of 17-21 mg/L, exceeding susceptibility breakpoints for most Gram-positive pathogens 3
Special Population Adjustments
Renal Insufficiency
While the parent drug pharmacokinetics are unchanged in renal dysfunction, dose reduction should be considered in patients with significant renal impairment to avoid metabolite accumulation and toxicity 2, 4:
- CrCl 60 mL/min: Consider 300 mg every 12 hours 5, 4
- CrCl 30-45 mL/min: Consider 200-300 mg every 12 hours 5, 4
- CrCl 15-30 mL/min: Consider 200 mg every 12 hours 5, 4
- Hemodialysis: Give 600 mg after dialysis sessions 2
Elderly Patients
The oldest old (≥75 years) are at particularly high risk for supratherapeutic concentrations 6. In elderly patients with renal insufficiency, start with reduced doses (300-400 mg every 12 hours) and consider therapeutic drug monitoring 6.
Critical Monitoring Parameters
Therapeutic Drug Monitoring (TDM)
Given the high variability in critically ill patients (AUC₂₄ ranging from 50-454 mg·h/L with standard dosing 7), TDM is strongly recommended for:
- Target trough concentration: 2-10 mg/L
- Timing: Obtain first level before the 7th dose (after 3 days of therapy) 6
- Supratherapeutic risk: Trough >10 mg/L associated with increased toxicity 7
- Subtherapeutic risk: 50-63% of ICU patients may have inadequate levels with standard dosing 7
Toxicity Surveillance
Monitor for dose-related toxicities during prolonged therapy 8:
- Hematologic: Weekly CBC for thrombocytopenia, anemia (especially >14 days)
- Neurologic: Peripheral neuropathy, optic neuropathy (especially >28 days)
- Metabolic: Lactic acidosis (rare but serious)
Duration of Therapy
For pneumonia, treat for 7-14 days based on clinical response 1. The specific duration for Corynebacterium pneumonia should be guided by:
- Clinical improvement (fever resolution, respiratory status)
- Radiographic improvement
- Source control if applicable
Common Pitfalls to Avoid
Failure to adjust for renal function: Unlike vancomycin where the parent drug requires adjustment, linezolid's metabolites accumulate in renal failure, necessitating dose reduction despite unchanged parent drug clearance 2, 4
Overlooking elderly patients: Age-related decline in renal function puts elderly patients at high risk for overexposure even with "normal" creatinine 6
Prolonged therapy without monitoring: Toxicity risk increases substantially after 14 days; TDM and hematologic monitoring become essential 8
Assuming therapeutic levels: Up to 63% of critically ill patients have subtherapeutic exposure with standard dosing 7, while 7% have toxic levels—TDM is not optional in severe infections